Catalyst Pharma Files 8-K, Confirms NASDAQ Listing

TL;DR

**Catalyst Pharma filed a routine 8-K, confirming its NASDAQ listing and standard compliance.**

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing primarily serves to update the public record regarding the company's current status and confirms its common stock, with a par value of $0.001 per share, is registered on the NASDAQ Capital Market. For investors, this filing is a routine update, indicating no immediate major operational or financial changes, but it reaffirms the company's compliance with SEC reporting requirements and its continued listing on a major exchange.

Why It Matters

This filing confirms Catalyst Pharmaceuticals' ongoing compliance with SEC regulations and its continued listing on the NASDAQ Capital Market, which is crucial for stock liquidity and investor confidence.

Risk Assessment

Risk Level: low — This 8-K filing is a standard procedural update and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating business as usual, and would look for more substantive news for investment decisions.

Key Numbers

• $0.001 — Par Value per Share (the stated par value of Catalyst Pharmaceuticals' common stock)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• NASDAQ Capital Market (company) — the exchange where Catalyst Pharmaceuticals' common stock is registered
• $0.001 (dollar_amount) — the par value per share of common stock
• January 9, 2024 (date) — the date of the earliest event reported in the 8-K

Forward-Looking Statements

• Catalyst Pharmaceuticals will continue to maintain its listing on the NASDAQ Capital Market. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: 2025-01-09

FAQ

From the Filing

0001193125-24-005292.txt : 20240109 0001193125-24-005292.hdr.sgml : 20240109 20240109171501 ACCESSION NUMBER: 0001193125-24-005292 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 24524117 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d702064d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-01-09 2024-01-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 9, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company   ☐              If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 8.01 Other Events On January 9, 2024, the Company issued a press release reporting the closing of its previously announced public offering of 10,000,000 shares of its common stock at an offering price of $15.00 per share. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and i